IFNG and neoplasm: Whereas, CD80−PD-L1+ human tumor cells anergized activated PD-1+ human PBMC and inhibited their production of IFNγ, CD80+PD-L1+ human tumor cells prevented anergy and maintained IFNγ production (90).